**Core Concept**
Trastuzumab is a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2/neu) protein, which is overexpressed in certain breast cancer cells. HER2/neu plays a crucial role in cell proliferation and survival.

**Why the Correct Answer is Right**
Trastuzumab works by binding to the extracellular domain of the HER2/neu receptor, preventing dimerization and subsequent activation of downstream signaling pathways. This action inhibits cell proliferation and induces apoptosis in HER2/neu-overexpressing cancer cells. However, **Option C** is incorrect because trastuzumab actually targets and downregulates the HER2/neu protein, not upregulates it.

**Why Each Wrong Option is Incorrect**
**Option A:** Trastuzumab has shown better response in combination with paclitaxel in clinical trials, particularly in HER2-positive metastatic breast cancer. This combination has improved patient outcomes.
**Option B:** Trastuzumab is indeed used in the treatment of metastatic breast cancer, particularly in HER2-positive cases.
**Option D:** Trastuzumab is generally well-tolerated, but it can cause bone marrow toxicity, including neutropenia, anemia, and thrombocytopenia, particularly when used in combination with other chemotherapy agents.

**Clinical Pearl / High-Yield Fact**
Trastuzumab is a targeted therapy that has revolutionized the treatment of HER2-positive breast cancer, offering improved survival rates and reduced toxicity compared to traditional chemotherapy agents.

**✓ Correct Answer: C. Causes upregulation of HER2/neu**